Q32 Bio, a Cambridge, Massachusetts-based biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases, raised $46m in Series A funding.
The round was led by Atlas Venture with participation from OrbiMed Advisors, Abingworth, Sanofi Ventures, University of Colorado and Children’s Hospital Colorado Center for Innovation.
Led by Michael Broxson, Chief Executive Officer, and co-founder, and Shelia Violette, Ph.D., Chief Scientific Officer and President of Research, Q32 Bio is a biotechnology company developing biologics to restore healthy immune regulation. The company has a product pipeline including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R), and a complement therapeutics platform that has generated fusion proteins that downregulate complement activity specifically in disease-affected tissues.
Q32 Bio’s most advanced program, ADX-914, is a fully human anti-IL-7R antibody licensed from Bristol Myers Squibb (NYSE: BMY) that re-regulates adaptive immune function.
Q32 Bio was seeded and incubated by Atlas Venture with foundational science from renowned researchers in immunology Michael Holers, M.D. and Joshua Thurman, M.D., both from the University of Colorado, and Steven Tomlinson, Ph.D. from the Medical University of South Carolina.